Dose tailoring of dabigatran etexilate: Obvious or excessive?

Expert Opinion on Drug Safety

Volumn 14, Issue 8, 2015, Pages 1283-1289

  Douxfils, Jonathan ^a   Mullier, François ^a,b   Dogné, Jean Michel ^a  

^a Facultes Universitaires Notre Dame de la Paix Faculte de Medicine   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Anticoagulant drugs; Benefit risk assessment; Dabigatran etexilate; Drug monitoring

Indexed keywords

DABIGATRAN ETEXILATE; ANTITHROMBIN; DABIGATRAN;

ANTICOAGULATION; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; PARTIAL THROMBOPLASTIN TIME; THROMBIN TIME; BLEEDING; CHEMICALLY INDUCED; DOSE RESPONSE; THROMBOSIS;

ANTITHROMBINS; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HEMORRHAGE; HUMANS; THROMBOSIS;

EID: 84937250263     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1049995     Document Type: Article

References (34)

1. Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients? JAMA 2015;313(10):1013-14
2. Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther 2014;39(6):628-36
3. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171(14):1285-6
4. McConeghy KW, Bress A, Qato DM, et al. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy 2014;34(6):561-9
5. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. Eng J Med 2013;368(14):1272-4
6. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Int Med 2015;175(1):18-24
7. Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc 2015;4(4):pii: e001798
8. Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167(3):329-34
9. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163(1):13-19; e1
10. Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011;162(4):606-12; e1
11. Food and Drug Administration. Pradaxa-Full Prescribing Information. 2015. Available from: http://www. accessdata. fda. gov/drugsatfda-docs/ label/2015/022512s024lbl. pdf [Cited 01 April 2015]
12. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15 Suppl 1:9S-16S
13. Food and Drug Administration. Pradaxa-Clinical Pharmacology and Biopharmaceutics Review(s). 2010. Available from: http://www. accessdata. fda. gov/drugsatfda-docs/ nda/2010/022512Orig1s000ClinPharmR. pdf [Cited 01 April 2015]
14. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now!. Thromb J 2013;11(1):8
15. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321-8
16. Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015;13(3):353-9
17. Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404-12
18. European Medicines Agency. Pradaxa-Summary of Product Characteristics. 2015. Available from: http://www. ema. europa. eu/docs/en-GB/document-library/ EPAR--Product-Information/ human/000829/WC500041059. pdf [Cited 01 April 2015]
19. European Medicines Agency. Pradaxa-EMEA/H/C/000829/X/13/G. 2011. Available from: http://www. ema. europa. eu/docs/en-GB/document-library/ EPAR--Assessment-Report--Variation/ human/000829/WC500110875. pdf [Cited 01 April 2015]
20. Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11(4):756-60
21. Baglin T, Keeling D, Kitchen S; British Committee for Standards in H. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159(4):427-9
22. Douxfils J, Mani H, Minet V, et al. Non-vka oral anticoagulants: Accurate measurement of plasma drug concentrations. Biomed Res Int 2014
23. Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013;110(2):308-15
24. Douxfils J, Dogne JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LCMS/ MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110(3):543-9
25. Douxfils J, Lessire S, Dincq AS, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015;113(4):862-9
26. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
27. Boehringer Ingelheim. An Idea for a Mid to Long Term Strategy for Pradaxa, showing EMA range comparisons. 2014. Available from: http://journals. bmj. com/site/bmj/dabigatran/compared- ema. pdf [Cited 01 April 2014]
28. Bounameaux H, Reber G. New oral antithrombotics: A need for laboratory monitoring. J Thromb Haemost 2010;8(4):627-30
29. Mismetti P, Laporte S. New oral antithrombotics: A need for laboratory monitoring. J Thromb Haemost 2010;8(4):621-6
30. Rao RB. Regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014;63(25 Pt A):2885
31. Douxfils J, Chatelain B, Dogne JM, Mullier F. Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. J Thromb Haemost 2015; doi: 10. 1111/jth. 12880. [Epub ahead of print]
32. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; doi: 10. 1016/S0140-6736(14) 61943-7. [Epub ahead of print]
33. Food and Drug Administration. Eliquis-Clinical Pharmacology and Biopharmaceutics Review(s). 2012. Available from: http://www. accessdata. fda. gov/drugsatfda-docs/ nda/2012/202155Orig1s000ClinPharmR. pdf [Cited 05 May 2015]
34. Food and Drug Administration. Xarelto-Clinical Pharmacology and Biopharmaceutics Review(s). 2011. Available from: http://www. accessdata. fda. gov/drugsatfda-docs/ nda/2011/022406Orig1s000ClinPharmR. pdf [Cited 18 April 2015]